Global cancer drug market trend

Source: Chengshu Investment May 20, 2014 global oncology trend report: Innovation in cancer care and implications for health systems We have made a comprehensive analysis of the global tumor drug market dynamics, R & D innovation, price trends, bio generic drugs, etc., and here we share the core content with you Market trends in 2013, the global market size of cancer drugs was US $91 billion (calculated by the factory price), and the CAGR from 2008 to 2013 was only 5.4% Compared with the average annual growth rate of 15% from 2003 to 2008, the growth rate from 2008 to 2013 was relatively slow The main reason is that there were few approved heavy-duty products in the field of cancer treatment in this period, while 2003-2008 The market of anti-tumor drugs grew rapidly during the year, which was driven by Avastin, Herceptin and other heavy-duty products Figure 1 From the regional perspective, the United States, the European Union and Japan are still the main players in the global anti-tumor drug market, accounting for 41%, 24% and 10% of the global anti-tumor drug market in 2013 Pharmaceutical emerging market countries (21 countries such as China, Brazil, Russia, India, etc.) have only 12% market share at present, but they have a rapid growth Between 2008 and 2013, CAGR was 16.8%, far exceeding the rest of the region Figure 2 The sub regions of the global tumor drug market in the past 10 years, the drug structure of the global anti-tumor field has also changed a lot In 2003, anti-tumor hormone drugs accounted for 48% of the market share, but in 2013, the proportion has dropped to 24%, instead of targeted treatment drugs (46%) In addition, there are great differences in drug use structure between developed countries and emerging market countries The proportion of targeted drugs in emerging market countries is only 27%, 19% lower than the global average Figure 3 The research and development of innovative anti-tumor drugs in the market structure of cancer treatment drugs from 2003 to 2013 is the research and development focus of major pharmaceutical enterprises At present, there are 6234 new drugs in active state in the world, including nearly 2000 anti-tumor drugs In preclinical and clinical phase I, 33% of new drugs under research are anti-tumor products; however, in the late stage of development, this proportion gradually decreases, so we can see the difficulty of anti-tumor drug development Figure 4 Statistics of new products under development in the world in the past 10 years, the approved new molecular entities (NMES) in the global anti-tumor field are mainly small molecule drugs, and the proportion of biological products is relatively small Figure 5 The price of new molecular entity drugs listed in the global anti-tumor field in 2004-2013 takes the United States as an example In 2013, the cost of anti-tumor brand drugs (i.e patent drugs) per month was about 10000 US dollars, doubled compared with the average of 5000 US dollars in 2003, and the monthly consumption of individual anti-tumor drugs even exceeded 30000 US dollars Figure 6 The average monthly cost of anti-tumor brand drugs in the United States According to the prediction of IMS, the global market of anti-tumor bio generic drugs will be between 6-12 billion US dollars in 2020, accounting for about 2% - 4% of the global market share of biological products From the perspective of market size, the United States will be the world's largest bio generic market Figure 7 Global anti-tumor bio generic market forecast 2011-2020 if you are interested in the full text of the report, you can also download the report on the official website of IMS The copyright of the report belongs to IMS IMS global oncology trend report: Innovation in cancer care and implications for health systems